Inhibition of sodium‐glucose cotransporter‐2 improves anaemia in mice and humans with sickle cell disease, and reduces infarct size in a murine stroke model
Journal of Cellular and Molecular Medicine · 2024
DOI: 10.1111/jcmm.70091 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, 2024. Verfasst von Jintao Wang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Cardiovascular Research Center, University of Michigan, Ann Arbor, Michigan, USA. Hauptthemen laut MEDLINE: Anemia, Sickle Cell, Sodium-Glucose Transporter 2 Inhibitors, Disease Models, Animal, Benzhydryl Compounds. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Michigan Pandemic Relief grant.
Themen: Schlaganfall
Abstract (Originalsprache)
Sodium‐glucose cotransporter‐2 (SGLT‐2) is expressed in the kidney and may contribute to anaemia and cardiovascular diseases. The effect of SGLT‐2 inhibition on anaemia and vascular endpoints in sickle cell disease (SCD) is unknown. A murine model of SCD was studied to determine the effects of the SGLT‐2 inhibitor, empagliflozin, on anaemia and stroke size. The University of Michigan's Precision Health Database was used to evaluate the effect of SGLT‐2 inhibitors on anaemia in humans with SCD. SCD mice treated with daily empagliflozin for 8 weeks demonstrated increases in haemoglobin, haematocrit, erythrocyte counts, reticulocyte percentage and erythropoietin compared to vehicle‐treated mice. Following photochemical‐induced thrombosis of the middle cerebral artery, mice treated with empagliflozin demonstrated reduced stroke size compared to vehicle treated mice. In the electronic health records analysis, haemoglobin, haematocrit and erythrocyte counts increased in human SCD subjects treated with an SGLT‐2 inhibitor. SGLT‐2 inhibitor treatment of humans and mice with SCD is associated with improvement in anaemic parameters. Empagliflozin treatment is also associated with reduced stroke size in SCD mice suggesting SGLT‐2 inhibitor treatment may be beneficial with regard to both anaemia and vascular complications in SCD patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Cardiovascular Research Center, University of Michigan, Ann Arbor, Michigan, USA.
- Chemical Pathology, University of Michigan, Ann Arbor, Michigan, USA.
ORCID-Profile: Jintao Wang
Förderung
- University of Michigan Pandemic Relief grant
Zitieren
APA
Wang, J., Silaghi, P., Guo, C., Harro, D., & Eitzman, D. T. (2024). Inhibition of sodium‐glucose cotransporter‐2 improves anaemia in mice and humans with sickle cell disease, and reduces infarct size in a murine stroke model. Journal of Cellular and Molecular Medicine. https://doi.org/10.1111/jcmm.70091
Vancouver
Wang J, Silaghi P, Guo C, Harro D, Eitzman DT. Inhibition of sodium‐glucose cotransporter‐2 improves anaemia in mice and humans with sickle cell disease, and reduces infarct size in a murine stroke model. Journal of Cellular and Molecular Medicine. 2024. doi:10.1111/jcmm.70091
BibTeX
@article{Wang2024,
author = {Wang, Jintao and Silaghi, Paul and Guo, Chiao and Harro, David and Eitzman, Daniel T},
title = {Inhibition of sodium‐glucose cotransporter‐2 improves anaemia in mice and humans with sickle cell disease, and reduces infarct size in a murine stroke model},
journal = {Journal of Cellular and Molecular Medicine},
year = {2024},
doi = {10.1111/jcmm.70091}
}
EUVIMED